Background/Aims: Secondary hyperparathyroidism may worsen after the administration of pamidronate in postmenopausal hemodialysis (HD) patients. The aim of this study was to evaluate the short-term effect of coadministration of calcitriol and pamidronate on dynamic parathyroid hormone (PTH) secretion. Methods: Fifteen postmenopausal women undergoing regular HD with serum intact PTH levels of >200 pg/ml were enrolled. The PTH-ionized calcium (iCa) curve was evaluated by the response to hypo- and hypercalcemia induced with 1 and 4 mEq/l of dialysate calcium, respectively. Parameters were compared after pamidronate was administered and after coadministration of pamidronate and calcitriol. Changes in serum levels of maximal serum PTH (PTHmax), basal PTH (PTHbase) and minimal PTH (PTHmin) were evaluated. Results: Pamidronate therapy resulted in a decrease in predialysis basal plasma iCa (p < 0.05) and an increase in PTHmax (p < 0.01), PTHbase (p < 0.01) and PTHmin (p < 0.01). The change in serum iCa and PTH was reversed after the coadministration of calcitriol and pamidronate. Conclusion: Our study demonstrated that pamidronate therapy is associated with a reduced plasma iCa and increased PTH secretion. These adverse effects may be reversed by calcitriol. These findings suggest that in considering pamidronate treatment in postmenopausal patients with osteoporosis receiving HD, it might be safer to add calcitriol to prevent the increased PTH secretion.

Keywords:
Bisphosphonate, Calcitriol, Postmenopause, Calcium set point, Secondary hyperparathyroidism
1.
Fraser WD: Hyperparathyroidism. Lancet 2009;374:145-158.
2.
Cunningham J, Locatelli F, Rodriguez M: Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913-921.
3.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
4.
Brown EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572-581.
5.
Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F: A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 1991;6:244-251.
6.
Gordon PL, Frassetto LA: Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis 2010;55:941-956.
7.
Eastell R: Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 2005;185:223-234.
8.
Fukagawa M, Hamada Y, Nakanishi S, Tanaka M: The kidney and bone metabolism: nephrologists' point of view. J Bone Miner Metab 2006;24:434-438.
9.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;(113):S1-S130.
10.
Miller PD: Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009;29:144-155.
11.
Lu KC, Ma WY, Yu JC, Wu CC, Chu P: Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism. Clin Endocrinol 2012;76:634-642.
12.
Malberti F, Farina M, Imbasciati E: The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2398-2406.
13.
Pahl M, Jara A, Bover J, Rodriguez M, Felsenfeld AJ: The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients. Kidney Int 1996;49:226-231.
14.
Valle C, Rodriguez M, Santamaria R, Almaden Y, Rodriguez ME, Canadillas S, Martin-Malo A, Aljama P: Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 2008;19:2430-2436.
15.
Bhan I, Thadhani R: Vitamin D therapy for chronic kidney disease. Semin Nephrol 2009;29:85-93.
16.
Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J: Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;79:1595-1599.
17.
Machado CE, Flombaum CD: Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996;45:175-179.
18.
Lu KC, Yeung LK, Lin SH, Lin YF, Chu P: Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 2003;42:1221-1227.
19.
Frazao JM, Martins P: Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens 2009;18:303-307.
20.
Buttazzoni M, Rosa Diez GJ, Jager V, Crucelegui MS, Algranati SL, Plantalech L: Elimination and clearance of pamidronate by haemodialysis. Nephrology 2006;11:197-200.
21.
Ruggiero SL: Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann NY Acad Sci 2011;1218:38-46.
22.
Miller PD: Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009;29:144-155.
23.
Bas S, Aguilera-Tejero E, Bas A, Estepa JC, Lopez I, Madueno JA, Rodriguez M: The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve. J Endocrinol 2005;184:241-247.
24.
Akerstrom G, Rastad J, Ljunghall S, Ridefelt P, Juhlin C, Gylfe E: Cellular physiology and pathophysiology of the parathyroid glands. World J Surg 1991;15:672-680.
25.
Fukagawa M, Kazama JJ, Shigematsu T: Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 2001;38(4 suppl 1):S152-S155.
26.
Felsenfeld AJ, Rodriguez M, Aguilera-Tejero E: Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2007;2:1283-1305.
27.
Rodriguez M, Nemeth E, Martin D: The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005;288:F253-F264.
28.
Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989;36:1093-1098.
29.
Rodriguez M, Caravaca F, Fernandez E, Borrego MJ, Lorenzo V, Cubero J, Martin-Malo A, Betriu A, Jimenez A, Torres A, Felsenfeld AJ: Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int 1999;56:306-317.
30.
Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 1993;43:771-789.
31.
Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F: The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 1991;2:1014-1020.
32.
Olaizola I, Aznarez A, Jorgetti V, Petraglia A, Caorsi H, Acuna G, Fajardo L, Ambrosoni P, Mazzuchi N: Are there any differences in the parathyroid response in the different types of renal osteodystrophy? Nephrol Dial Transplant 1998;13(suppl 3):15-18.
33.
Ettinger B, Genant HK, Cann CE: Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-324.
34.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
35.
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
36.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
37.
Fleisch H: Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
38.
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
39.
Bergner R, Henrich D, Hoffmann M, Schmidt-Gayk H, Lenz T, Upperkamp M: Treatment of reduced bone density with ibandronate in dialysis patients. J Nephrol 2008;21:510-516.
40.
Bergner R: Bisphosphonate therapy in renal osteodystrophy - a review. J Nephrol 2012, E-pub ahead of print.
41.
Whitson HE, Lobaugh B, Lyles KW: Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 2006;39:954-958.
42.
Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K: Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006;12:48-53.
43.
Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, Zeni S: Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Neuronal Interact 2005;5:174-181.
44.
Saha H, Ala-Houhala I, Ylitalo P, Kleimola T, Pasternack A: Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients. Clin Nephrol 2002;58:47-53.
45.
Toussaint ND, Elder GJ, Kerr PG: Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009;4:221-233.
46.
Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM; Fracture Intervention Research Group: Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 2006;21:292-299.
47.
Ott SM: Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int 2012;82:833-835.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.